Houston-based March Biosciences, launched from the Center for Cell and Gene Therapy (Baylor College of Medicine, Houston Methodist Hospital, Texas Children's Hospital), is dedicated to addressing challenging cancers unresponsive to current immunotherapies. Its lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia, with promising signals of efficacy and safety to date. A Phase 2 trial is expected to begin next early year. The company has raised over $50M to date, inclusive of this current financing and support from the Cancer Prevention & Research Institute of Texas (CPRIT) and the NIH SBIR program.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/23/24	$28,400,000	Series A	4BIO Capital Alexandria Venture Investments Cancer Focus Fund KdT Ventures Mansueto Investments Mission BioCapital Modi Ventures Portal Innovations Small Ventures USA TMC Venture Fund Volnay Therapeutics	undisclosed